The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
BrainStorm announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn for the treatment of ALS.
read more
Regeneron and Sanofi announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe ...
read more
SU2C has awarded 10 Catalyst clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate ...
read more
Prometic Life Sciences announced the FDA has accepted its BLA for its plasminogen replacement therapy Ryplazim.
read more
Prometic Life Sciences announced the FDA has accepted its BLA for its plasminogen replacement therapy Ryplazim.
read more
Wednesday, October 11, 2017
Ansun BioPharma announced the FDA has granted Breakthrough Therapy Designation to experimental compound DAS181.
read more
Wednesday, October 11, 2017
MilliporeSigma today officially opened its new Life Science Center in Burlington, Massachusetts.
read more
Tuesday, October 10, 2017
Mundipharma EDO GmbH has begun a U.S. Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid tumors.
read more
Tuesday, October 10, 2017
The National Multiple Sclerosis Society has committed nearly $14 million to support 40 new MS research projects.
read more
The FDA awarded 15 new clinical trial research grants totaling more than $22 million to boost development of products for patients with rare diseases.
read more
Bristol-Myers Squibb has appointed Saurabh Saha, M.D., Ph.D. as senior vice president and global head of translational medicine in the company’s R&D ...
read more
Kadmon announced the FDA has granted orphan drug designation to KD025 for the treatment of chronic graft-versus-host disease.
read more
Thursday, October 05, 2017
In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy effectively stabilized the disease's progression in 88 percent of ...
read more
Wednesday, October 04, 2017
Viking Therapeutics announced positive top-line results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked ...
read more
Tuesday, October 03, 2017
AOBiome announced the initiation of patient enrollment in AOBiome's Phase 1b/2a clinical trial of the company's AOB product candidate, for the ...
read more